Last reviewed · How we verify
Aolanti Weikang tablets
At a glance
| Generic name | Aolanti Weikang tablets |
|---|---|
| Sponsor | Jiangxi Qingfeng Pharmaceutical Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase Ⅱc Sutdy of Aolanti Weikang Tablets in FD PDS Patients (PHASE2)
- Study of Aolanti Weikang Tablets in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aolanti Weikang tablets CI brief — competitive landscape report
- Aolanti Weikang tablets updates RSS · CI watch RSS
- Jiangxi Qingfeng Pharmaceutical Co. Ltd. portfolio CI